Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA
NCT ID: NCT03039634
Last Updated: 2019-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
76 participants
OBSERVATIONAL
2016-08-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
NCT03303170
Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
NCT02219074
Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
NCT02217228
A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris
NCT06671834
Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris
NCT00098358
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has followed predecessor study restrictions prior to study entry.
* Subject is able to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA); minors will in addition have parent or legal guardian provide consent.
* Subject is willing to comply with the schedule, procedures, and restrictions of the study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sienna Labs
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Lizzul, MD
Role: STUDY_DIRECTOR
Sienna Biopharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scottsdale, Arizona, United States
Santa Monica, California, United States
Coral Gables, Florida, United States
Miami, Florida, United States
Hunt Valley, Maryland, United States
Beverly, Massachusetts, United States
St Louis, Missouri, United States
Hackensack, New Jersey, United States
Charlotte, North Carolina, United States
Yardley, Pennsylvania, United States
Charleston, South Carolina, United States
Houston, Texas, United States
Pflugerville, Texas, United States
San Antonio, Texas, United States
Jordan, Utah, United States
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SL-2016-01_FA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.